Literature DB >> 3203053

Nonlinear accumulation of propranolol enantiomers.

R L Lalonde1, M B Bottorff, R J Straka, D M Tenero, J A Pieper, I W Wainer.   

Abstract

The accumulation of (+)- and (-)-propranolol was investigated in nine subjects who received 160 mg of racemic propranolol as a single dose and then once daily for 7 days. The serum concentrations of propranolol enantiomers were measured by h.p.l.c. using a novel chiral stationary phase allowing direct resolution of underivatized propranolol. The (+)-propranolol AUC increased from 412 +/- 223 ng ml-1 h after single doses (0-infinity) to 584 +/- 279 ng ml-1 h at steady-state (0-24 h) (P less than 0.05). Similarly, (-)-propranolol AUC increased from 609 +/- 304 to 777 +/- 370 ng ml-1 h (P less than 0.05). The AUC ratio (-)/(+) was 1.52 +/- 0.36 and 1.32 +/- 0.17 after single doses and steady-state, respectively (P greater than 0.05). Therefore, nonlinear accumulation occurs with both enantiomers although there is a trend for the (-)/(+) ratio to decrease at steady-state.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3203053      PMCID: PMC1386507          DOI: 10.1111/j.1365-2125.1988.tb03371.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Nonlinear pharmacokinetics of unbound propranolol after oral administration.

Authors:  R J Straka; R L Lalonde; J A Pieper; M B Bottorff; D M Mirvis
Journal:  J Pharm Sci       Date:  1987-07       Impact factor: 3.534

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Measurement of underivatized propranolol enantiomers in serum using a cellulose-tris(3,5-dimethylphenylcarbamate) high-performance liquid chromatographic (HPLC) chiral stationary phase.

Authors:  R J Straka; R L Lalonde; I W Wainer
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

4.  Direct measurement of propranolol bioavailability during accumulation to steady-state.

Authors:  A J Wood; K Carr; R E Vestal; S Belcher; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

5.  Stereoselective disposition and glucuronidation of propranolol in humans.

Authors:  B Silber; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1982-06       Impact factor: 3.534

6.  Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity.

Authors:  C von Bahr; J Hermansson; M Lind
Journal:  J Pharmacol Exp Ther       Date:  1982-08       Impact factor: 4.030

7.  Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.

Authors:  S A Bai; M J Wilson; U K Walle; T Walle
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

  7 in total
  2 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay.

Authors:  M Piquette-Miller; F Jamali
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.